Review: amisulpride is effective and safe for schizophrenia.
نویسندگان
چکیده
Main results 18 studies (2214 patients) met the selection criteria. Study duration ranged from 3 weeks to 1 year (mean 12 wks). Patients were mostly men in their 30s with moderate to severe schizophrenia (mean duration 3–37 y). Comparators were usually haloperidol and placebo; 4 studies compared amisulpride with flupentixol, perazine, and fluphenazine. Amisulpride led to a greater mean reduction in BPRS score from baseline than conventional antipsychotics in acutely ill patients (table). In patients with persistent, predominantly negative symptoms, amisulpride was better than placebo (but not conventional antipsychotics) for mean change in negative symptoms (table). In patients with acute exacerbations, amisulpride led to a greater mean change in negative symptoms relative to conventional antipsychotics (table). Amisulpride was better than conventional antipsychotics but was not different from placebo (which was compared with low dose amisulpride, 50–300 mg/d) for use of antiparkinsonian drugs (table). In acutely ill patients, fewer patients treated with amisulpride than with conventional drugs dropped out (table). In patients with predominantly persistent negative symptoms, fewer patients in the amisulpride group than in the placebo group dropped out; amisulpride and conventional antipsychotics did not differ for dropouts (table).
منابع مشابه
Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia.
BACKGROUND Amisulpride is a substituted benzamide with high selectivity for dopamine D2 and D3 receptors. The purpose of the study was to evaluate the effect of 100 mg amisulpride in patients with predominantly negative symptoms of schizophrenia. METHOD This was a multi-centre, randomised, parallel-group, double-blind study. Patients received either amisulpride (100 mg/day) or placebo over a ...
متن کاملSafety and tolerability of antipsychotics: focus on amisulpride
The introduction of the atypical antipsychotic drugs represents an important advance in the treatment of schizophrenia, because the therapeutic efficacy, tolerability, and safety profiles of these agents seem to be superior to that of the classical neuroleptics. As would be predicted from the pharmacologic profile of a pure D(2)/D(3) receptor blocker, amisulpride is an atypical antipsychotic ag...
متن کاملAmisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials.
OBJECTIVE The "atypical" profile of the new antipsychotics clozapine, olanzapine, quetiapine, and risperidone has been linked to combined antagonism of serotonin 2 (5-HT(2)) and dopamine 2 (D(2)) receptors. Although amisulpride is a highly selective D(3)/D(2) receptor antagonist, it is assumed to have atypical properties as well. The purpose of this article was to compare the atypical profile o...
متن کاملUpdate on the management of symptoms in schizophrenia: focus on amisulpride
Amisulpride is an atypical antipsychotic drug with a unique receptor pharmacology which is dose dependent. It is a standard treatment in dysthymia as well as in psychosis. Amisulpride is efficacious, effective and well tolerated in positive symptoms of schizophrenia: there is extensive evidence that it treats negative symptoms when given in low doses, although relative lack of EPS and an antide...
متن کاملEffectiveness of amisulpride in Chinese patients with predominantly negative symptoms of schizophrenia: a subanalysis of the ESCAPE study
BACKGROUND Effective management strategies for the negative symptoms of schizophrenia remain an unmet need, and data on the use of antipsychotics in this population are scarce, particularly in Chinese patients. Therefore, we investigated amisulpride for the treatment of Chinese patients with predominantly negative symptoms of schizophrenia. METHODS This post hoc subanalysis of the prospective...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Evidence-based mental health
دوره 5 3 شماره
صفحات -
تاریخ انتشار 2002